Gabriella De Salvo

Dr. Gabriella De Salvo

Southampton Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2010 in Eye
Verified
Journal Article
Closed access
PDF file
MGM Gemenetzi
M Gemenetzi
Gabriella De SalvoGabriella De Salvo
Gabriella De Salvo
ALAndrew J Lotery
Andrew J Lotery

1 December 2014 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
Gabriella De SalvoGabriella De Salvo
Gabriella De Salvo
Sara Vaz-PereiraSara Vaz-Pereira
Sara Vaz-Pereira
PKPearse Keane
Pearse Keane
ATAdnan Tufail
Adnan Tufail
GLGerald Liew
Gerald Liew

1 December 2006 in Ophthalmology
Verified
Journal Article
Closed access
ALAlbert Lin
Albert Lin
RFRod Foroozan
Rod Foroozan
HDHelen V. Danesh-Meyer
Helen V. Danesh-Meyer
Gabriella De SalvoGabriella De Salvo
Gabriella De Salvo
PSPeter J. Savino
Peter J. Savino
RSRobert C. Sergott
Robert C. Sergott

1 February 2015 in Clinical Ophthalmology
Verified
Journal Article
Open access
PKPearse Keane
Pearse Keane
Gabriella De SalvoGabriella De Salvo
Gabriella De Salvo
DSDawn Sim
Dawn Sim
SGSrini Goverdhan
Srini Goverdhan
RARupesh Agarwal
Rupesh Agarwal
ATAdnan Tufail
Adnan Tufail
Treatment of the neovascular form of age-related macular degeneration (AMD) has been revolutionized by the introduction of such agents as ranibizumab, bevacizumab, and aflibercept. As a result, the incidence of legal blindness occurring secondary to AMD has fallen dramatically in recent years in many countries. While these agents have undoubtedly been successful in reducing visual impairment and blindness, patients with neovascular AMD typically lose some vision over time, and often lose the ability to read, drive, or perform other important activities of daily living. Efforts are therefore under way to develop strategies that allow for earlier detection and treatment of this disease. In this review, we begin by providing an overview of the rationale for, and the benefits of, early detection and treatment of neovascular AMD. To achieve this, we begin by providing an overview of the pathophysiology and natural history of choroidal neovascularization, before reviewing the evidence from both clinical trials and “real-world” outcome studies. We continue by highlighting an area that is often overlooked: the importance of patient education and awareness for early AMD detection. We conclude the review by reviewing an array of both established and emerging technologies for early detection of choroidal neovascularization, ranging from Amsler chart testing, to hyperacuity testing, to advanced imaging techniques, such as optical coherence tomography.

1 August 2010 in Ophthalmology
Verified
Journal Article
Closed access
IKIlse Krebs
Ilse Krebs
SHStefan Hagen
Stefan Hagen
WBWerner Brannath
Werner Brannath
PHPaulina Haas
Paulina Haas
IWIrene Womastek
Irene Womastek
SBSusanne Binder
Susanne Binder

20 February 2013 in British Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
SHShabeeba Rashed Hannan
Shabeeba Rashed Hannan
Gabriella De SalvoGabriella De Salvo
Gabriella De Salvo
ASAlina Stinghe
Alina Stinghe
FSFatima Shawkat
Fatima Shawkat
ALAndrew J Lotery
Andrew J Lotery
Objectives (1) To investigate and integrate the tomographic, angiographic and electrodiagnostic findings in pattern dystrophy. (2) To correlate visual acuity (VA) with central macular thickness (CMT), the electrooculogram (EOG) and pattern electroretinogram (PERG). Design A retrospective study of patients with pattern dystrophy. 52 eyes of 26 patients were examined. Results Thirty-three eyes had adult-onset foveomacular vitelliform dystrophy, 8 had multifocal pattern dystrophy, 6 had butterfly pattern dystrophy and 2 had reticular pattern dystrophy. SD-OCT demonstrated hyperreflectivity between the retinal pigment epithelium (RPE)/ Bruch's complex, and the junction of the inner and outer segments (IS/OS) of the photoreceptors. Disruption of the IS/OS was observed in 20, and disruption of the end tips of photoreceptors was clearly visible in eight eyes. 11 eyes showed abnormal focal hyper-reflectivity originating from the RPE towards the outer nuclear layer (ONL), and in two eyes this appeared to originate from the junction of the IS/OS towards the ONL. EDTs revealed borderline or a reduced EOG in 25 (51%) and a degraded PERG in 41eyes (83.6%) with the P50 component reduced in 23 and N95 in 18. CMT and Arden ratio did not show any significant correlation with VA. Conclusions We observed relatively consistent features between different types of pattern dystrophies. In addition we observed novel findings on 3D-OCT. We also report 3D-OCT features of reticular, multifocal and butterfly pattern dystrophies. The degraded PERG results observed in our study indicate that the disease process in this condition is not limited to the RPE.